|Description||Daporinad, also known as APO-866 (FK866), is a small molecule with potential antineoplastic and antiangiogenic activities. In addition, this agent may inhibit tumor cell prioduction of vascular endothelial growth factor (VEGF), resulting in the inhibition of tumor angiogenesis. The coenzyme NAD+ plays an essential role in cellular redox reactions, including the redox reaction linking the citric acid cycle and oxidative phosphorylation.|
|Appearance||Light yellow to yellow solid|
|Synonyms||APO-866; APO866; FK866.|
|Current Developer||TopoTarget USA, Inc.|
Daporinad, also known as APO-866 (FK866), is a small molecule with potential antineoplastic and antiangiogenic activities. In addition, this agent may inhibit ...
CB 300919 is a water-soluble analogue of CB30865; has a continuous exposure (96 h) growth inhibition IC50 value of 2 nM in human CH1 ovarian tumor xenograft.
CHS-828 is a synthetic guanidine-based small anticancer molecule. CHS 828 was found to exert potent cytotoxic effects in human breast and lung cancer cell lines...
STF-118804 is a potent and highly specific NAMPT inhibitor, which improves survival in an orthotopic xenotransplant model of high-risk acute lymphoblastic leuk...
CB30865 is a highly potent cytotoxic agent. The compound inhibits isolated mammalian thymidylate synthase (TS), but this inhibition is insufficient to account f...
GNE-617 is a novel and specific Nampt inhibitor with an IC50 of 18.9 nM in A549 cell.
Nampt-IN-1, a pyridyloxyacetyl tetrahydroisoquinoline compound, is a novel inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) with the potential to tre...